Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of systematic versus work-up-guided radioiodine in intermediate-risk differentiated thyroid cancer
2019-002968-27Phase 3Active
- Sponsor
- Centre François Baclesse
- Start
- Dec 2019
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of iodine-131 in well-differentiated thyroid cancer (WDTC) (2 arms), sponsored by Centre François Baclesse. Primary endpoint: Excellent response rate at 3 years. Started Dec 2019; status: active.
02
Drugs
iodine-131
03
Conditions
well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on 2019-002968-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002968-27.